| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_067a3c5fff599aa564fefd4d03be8fde |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 |
| filingDate |
2017-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_589133cdb08fbbe3831a52f51c1b3c13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1e82e0e3370c24ed7dd22e3233737ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cade60e0aeb9553f3c13191d1a8963be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2658c6c6e6755758d7d8b41d19d9084a |
| publicationDate |
2018-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10092543-B2 |
| titleOfInvention |
Methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors |
| abstract |
Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE). |
| priorityDate |
2013-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |